9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelin Positive

Estimated Enrollment: 134

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Recommended phase 2 dose of anetumab ravtansine with combination of pembrolizumab,  Confirmed tumor response rate assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria (Phase II),  Duration of response defined as evaluable patients who achieved noted to be a partial response or complete response based Response Evaluation Criteria in Solid Tumors version 1.1 criteria, Overall survival

Interventions: Anetumab Ravtansine, Laboratory Biomarker Analysis

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: February 2, 2020

Completion Date: February 2, 2020

Last  Posted Date: July 23, 2019

Location: Mayo Clinic Hospital, Phoenix, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT03126630

Was this article helpful?
Dislike 0